Masking policy

Patients, help us protect our high-risk patients - please wear a mask if you have respiratory symptoms, a positive COVID-19 test, or COVID-19 exposure.

Effective 3/13/23, ARC transitions to optional masking for our staff and physicians, with required masking during specific situations. Read more.

Renewing Medicaid Coverage Update

In response to the COVID-19 pandemic, the federal government declared a public health emergency (PHE) and passed a law that allowed you to automatically keep your Medicaid coverage (continuous Medicaid). Based on the new federal law, continuous Medicaid eligibility will end on March 31, 2023, so you need to renew your benefits when it’s time to ensure your coverage will continue if you are eligible.

Patients should look for notices from HHSC in YELLOW envelopes that say "ACTION REQUIRED" in RED lettering. Notices will come in the mail and/or via portal if clients chose electronic notices. They should respond quickly when they receive it.

If you don’t respond to renewal or information requests from HHS, you could lose your coverage.

Read more

Actualización Sobre Renovando la Cobertura de Medicaid 

Como respuesta a la pandemia de COVID-19, el gobierno federal declaró una Emergencia de Salud Pública (PHE, por sus siglas en inglés) y aprobó una ley que le permitió a usted mantener automáticamente su cobertura de Medicaid (cobertura continua de Medicaid). Según la nueva ley federal, la elegibilidad para la cobertura continua de Medicaid se terminará el 31 de marzo, de 2023, por eso necesita renovar sus beneficios cuando se llegue el momento para asegurar que su cobertura va a continuar si usted todavía es elegible.

Pacientes deben buscar avisos de la HHSC en sobres AMARILLOS con el texto “ACCIÓN REQUERIDA” en letras ROJAS. Los avisos llegarán por correo y/o a través del portal en línea si los clientes eligieron recibir avisos electrónicos. Deberían responder con rapidez cuando lo reciban. 

Si no responde a las solicitudes de renovación o de información de la HHSC, podría perder su cobertura.

Leer más

ARC MyChart downtime

ARC MyChart downtime: Due to technical maintenance, ARC MyChart will be unavailable 7:00pm Saturday, April 1 to 7:00am Sunday, April 2. To schedule an appointment during this time, please call 512-272-4636 and press "1". You can reach all-night phone nurses by calling any clinic and pressing “4” to speak with a nurse.

MyChart Login Help Me Book

Pediatric Chickenpox Vaccine Clinical Study

Austin Regional Clinic physicians constantly try to improve the care given to all our patients. We are dedicated to offering unique options for our patients and helping them reach their ideal health goals. Part of this dedication involves making clinical research available. Clinical research makes it possible to discover the benefits, risks, and safety of commercially available and investigational medications.

Research standards are very strict to help make studies as safe as possible. Teams of government and research experts have already reviewed each study we conduct to minimize any study risks. Austin Regional Clinic has decided to be involved in this research study because we believe it can potentially benefit our patients.

About the pediatric chickenpox vaccine clinical study

Varicella, more commonly known as chickenpox, is a highly contagious infectious disease caused by the varicella-zoster virus, which can cause serious complications in children. The trial is studying an investigational vaccine to help prevent chickenpox in 12-15 month olds. This study looks at different strengths of a potential new investigational vaccine (called the "study vaccine") against chickenpox. The study vaccine will be compared with an approved chickenpox vaccine, Varivax® (called the "reference vaccine"). Varivax® has been available for use in the USA since 1995. Access to several chickenpox vaccines is important because vaccination is the only way to help protect children from chickenpox.

Children who are 12-15 months of age, in good health, and have received the first 3 doses (primary series) of a pneumococcal conjugate vaccine may qualify.

What to expect

  • You will be asked to come to our research clinic 3 times
  • Your child's health will be evaluated at each appointment by our research nurse and physician
  • All study-related care and evaluations will be at no cost to you or your insurance
  • You will be compensated for your time and travel
  • If you choose for your child to take part in the study, you can choose for your child to stop participating at any time

What will this study involve?

If your child takes part, they will be in this study for about 6 months. Your child will need to:

  • Complete 3 study visits and 2 phone contacts for safety follow-up.
  • Receive the study vaccine or reference vaccine and 3 other approved vaccines that are part of routine vaccination schedules:
    • M-M-R II® against measles, mumps, and rubella
    • Havrix® against hepatitis A infection
    • Prevnar 13®, a pneumococcal conjugate vaccine, against infections caused by the Streptococcus pneumoniae bacteria, which cause ear, lung, and other infections
  • Have 1 blood sample collected about 6 weeks after vaccination.
    • The collected blood sample will be used to assess if your child has developed an immune response to the study vaccine or the reference vaccine. If your child has not developed an immune response, your child will be re-vaccinated with the reference vaccine.

Location

Number of visits required

  • 3 office visits

Request to Participate

Participate in a Trial

Are you interested in a particular study opportunity? For more information on how to participate in a study, please contact our ARC research team at 512-225-5931.